Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer-Reference-Cited by-同舟云学术

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

Published:2023-01 Issue: Volume:178 Page:70-81
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Swain Sandra M.,Tan Antoinette R.,Gianni Luca,Kuemmel Sherko,Dang Chau T.,Schneeweiss Andreas,O'Shaughnessy Joyce,Liu Haiying^ORCID,Aguila Christian^ORCID,Heeson Sarah,Macharia Harrison^ORCID,Yang Ke,Restuccia Eleonora,Loibl Sibylle^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019

2. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

3. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021;Burstein;Ann Oncol,2021

4. European Commission approves Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer;Hoffmann-La Roche Ltd,2020

5. PERJETA® (pertuzumab). Summary of product characteristics,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome;Life;2024-03-18